For Non-Small Cell Lung Cancer (NSCLC), VAL-083 Demonstrates Effectiveness
the Cancer Therapy Advisor take:
According to new findings presented at the American Association for Cancer Research's (AACR) New Horizons in Cancer Research: Harnessing Breakthroughs - Targeting Cures in Shanghai, China, a new drug compound currently known as VAL-083 was shown to be superior to cisplatin for the treatment of non-small cell lung cancer (NSCLC).
The results demonstrated that VAL-083 is superior to cisplatin in tumors that are either sensitive or resistant to tyrosine kinase inhibitors (TKI), and it was found to have a synergistic effect when combined with cisplatin.
VAL-083 (dianhydrogalactitol) is the first agent in a class of alkylating agents that have a novel cytotoxic mechanism. The drug has demonstrated clinical activity in various types of cancers, including central nervous system tumors, solid tumors, and hematologic cancers. VAL-083 is approved for the treatment of lung cancer and chronic myelogenous leukemia (CML) in China. In the United States, VAL-083 is in a phase 1/2 clinical trial to study its efficacy in the treatment of glioblastoma multiforme.
NSCLC is typically treated with either a TKI, such as gefitinib, or a platinum-containing regimen. Despite improved outcomes seen with the use of TKIs, there are not many options for patients with TKI resistance.
VAL-083 was shown to be superior to cisplatin for the treatment of non-small cell lung cancer.
DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.
"The data presented today showed that VAL-083 is superior to cisplatin in both tumor models that are sensitive and resistant to tyrosine kinase inhibitors and has synergistic effect in combination with cisplatin," said Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals. "This data suggests important clinical and market potential of VAL-083 in non-small cell lung cancer."
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer